Global trends and knowledge structure of graphene based cancer research between 2016 and 2025 Authors: Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Hazem Mathkour, Edrous Alamer, Saleh Mohammad Abdullah, Saeed Alshahrani, Nizar A. Khamjan, Abdullah Farasani, Ahmed S. Alamer, Jobran M. Moshi, Khaled A. Sahli, Mohammed Jeraiby, Marwa Qadri, Abdulwahab Binjomah, Khloud H. Alsaadi, Hussam M. Shubaily, Bandar Mushin Alamri Published: 2025 ABSTRACT BackgroundGraphene-based nanomaterials are increasingly explored for cancer diagnosis and therapy, yet a comprehensive mapping of their scholarly landscape is lacking.MethodsOn 13 March 2025, a total of 4917 records (2016–2025) were retrieved from the Scopus database using a multistep search strategy. Bibliometric indicators were analyzed with Bibliometrix (R-package), VOSviewer, and CiteSpace to evaluate research growth, collaboration, intellectual structures, and thematic evolution.ResultsPublications grew at an annual rate of 2.97%, with China leading in both productivity and citations. Bradford’s Law identified 21 core journals, and leading contributors included LI Y and ZHANG Y. Collaboration networks showed dense interinstitutional and international links, particularly across Asia. Keyword and thematic analyses highlighted enduring focuses such as “graphene oxide,” “drug delivery,” and “biosensors,” while emerging trends included “plasmon resonance biosensor,” “brain tumor detection,” and advanced therapeutic applications. Co-citation and overlay mapping revealed conceptual shifts toward precision diagnostics and targeted therapies.ConclusionThis study provides the first integrated bibliometric roadmap of graphene-based cancer research (2016–2025), outlining its growth trajectory, knowledge structures, and evolving themes. Findings inform researchers, funding agencies, and policymakers on current strengths, translational challenges, and priority directions for advancing graphene-based innovations in oncology.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-025-04341-x. Introduction Graphene and its derivatives have attracted increasing attention in oncology research due to their exceptional physicochemical properties [1], including a large surface area, superior mechanical strength, thermal conductivity, and potential biocompatibility [2]. These characteristics allow graphene to act as a multifunctional platform in cancer diagnosis and treatment, especially through its ability to be functionalized with targeting ligands, imaging agents, and therapeutic molecules [3–5]. Among its most promising applications is drug delivery, where graphene oxide (GO) and reduced graphene oxide (rGO) have been extensively studied for their capacity to deliver chemotherapeutic agents directly to tumor cells with enhanced efficacy and minimal off-target toxicity [2, 6]. For instance, rGO functionalized with lipids and antioxidant enzymes selectively inhibited the proliferation of metastatic cancer cells while sparing normal cells [6, 7]. Similarly, GO combined with doxorubicin (GO-DOX) showed enhanced inhibition of breast cancer stem cells, indicating synergistic anticancer effects [8]. Another valuable application lies in photothermal therapy, where graphene’s photothermal conversion capabilities enable localized hyperthermia upon near-infrared light irradiation, effectively inducing tumor cell apoptosis [6, 9]. Moreover, GO has been explored in combination with radiotherapy to target cancer stem cells, reducing the likelihood of recurrence and metastasis [4]. The antitumor mechanisms of graphene involve a combination of oxidative stress induction, mitochondrial dysfunction, apoptosis, and inhibition of metastasis. Several studies have shown that rGO induces dose-dependent cytotoxicity and apoptotic cell death in breast cancer lines by generating reactive oxygen species (ROS) [10, 11]. Notably, composites such as GO-silver nanoparticles further amplify ROS production and mitochondrial damage, effectively targeting resistant ovarian cancer stem cells [2]. In addition to inducing apoptosis, pristine graphene and GO can suppress cancer cell migration and invasion by disrupting ATP production and impairing cytoskeleton organization, thus impeding metastatic progression [5]. Functionalization enhances selective cytotoxicity, allowing for preferential targeting of malignant cells while minimizing adverse effects on normal tissues [7, 12]. However, concerns regarding long-term toxicity remain significant. Graphene materials have been linked to pulmonary inflammation, oxidative damage, and even promotion of tumor metastasis through Wnt pathway activation via damage-associated molecular patterns (DAMPs) [1]. To overcome these limitations, researchers are developing graphene composites using biocompatible polymers and targeting molecules to enhance safety and therapeutic precision [3, 13]. Graphene-based nanomaterials have advanced rapidly in oncology across diagnostics, sensing, and therapy, yet research remains fragmented across disease- or modality-specific strands, such as breast cancer [14] bone cancer therapy with graphene oxide [15], nanovaccines [16], or broader nanomaterial toxicity trends [17], rather than integrated at the field level [14, 15, 17, 18]. While these studies provide valuable insights, none have comprehensively mapped global research trends, collaboration dynamics, and thematic evolution across multiple cancer types. To address this gap, we present a bibliometric synthesis of Scopus-indexed publications (2016–2025; search date: 13 March 2025), a period selected to capture exponential growth in graphene-related biomedical research following post-2015 advances in functionalization, biosafety profiling, and translational strategies. Recent field-mapping studies across disparate domains—4D printing in computer engineering, quantum computing knowledge visualization, AI for environmental sustainability, and computer applications in education [19, 20]—demonstrate that triangulated bibliometrics can reveal growth trajectories, collaboration architectures, and conceptual shifts that are directly actionable for funders and practitioners. Building on these precedents, our study adopts a multi-tool workflow (Bibliometrix, VOSviewer, CiteSpace) to integrate co-authorship, co-citation, overlay timelines, and thematic evolution for graphene-based cancer research. Materials and methods Source justification and data extraction The decision to use Scopus as the sole source of data was made because of its extensive coverage of peer-reviewed literature and scanned scientific domains for structured metadata, which makes it appropriate for bibliometric analysis. Scopus outperforms both Web of Science and PubMed in terms of journal coverage and citation tracking, author profiling, and keyword mapping [21]. This makes it especially valuable for capturing emerging trends, collaboration networks, and thematic evolution in interdisciplinary domains like graphene-based cancer research. A comprehensive data retrieval process was conducted using the Scopus database on March 13, 2025, to identify relevant publications on the application of graphene in cancer research. The initial search query [(TITLE-ABS-KEY ("graphene" OR "graphene oxide" OR "graphitic" OR "carbon allotrope") AND TITLE-ABS-KEY ("cancer" OR "tumor" OR "neoplasm" OR "malignancy")) AND (LIMIT-TO (DOCTYPE, "ar")) AND (LIMIT-TO (LANGUAGE, "English"))] was designed to include broad terminology related to graphene and cancer. This query, applied to the Title-Abstract-Keyword fields, yielded 8065 documents. To refine the dataset and ensure analytical relevance, we limited the results to English-language original research articles, reducing the dataset to 5747 documents. The corpus was cross-checked against PubMed and Web of Science, and Scopus demonstrated broader coverage in terms of both document numbers and citation data. Filters applied were: publication years (2016–2025), language (English), and document type (articles and reviews). The initial search returned 5462 records. After excluding conference proceedings, editorials, and non-English publications, 5103 records remained. Following duplicate removal and relevance screening, 4917 unique records were included for analysis. A PRISMA-style flow diagram (Fig. 1) illustrates the selection process.Fig. 1Data extraction process based on PRISMA guidelines. Note: Data for 2025 represent a partial year and may not reflect complete publication or citation trends Data extraction process based on PRISMA guidelines. Note: Data for 2025 represent a partial year and may not reflect complete publication or citation trends The raw dataset exported from Scopus (search date: 13 March 2025) included standard bibliographic fields such as authors, author IDs, title, year, source title, volume/issue, DOI, affiliations, abstract, author keywords, index keywords, cited-by counts, references, and funding details. Additional metadata (e.g., document type, ISSN, publisher, conference information, and open-access status) were also retained. Data types comprised categorical (e.g., document type, language), numeric (e.g., page counts, citation counts), and string variables (e.g., author names, titles). The time range spanned 2016–2025. No personally identifiable or sensitive information was included; all records reflected public bibliographic metadata. The dataset was exported in CSV format for Bibliometrix (R-package), while RIS/BibTeX formats were generated where required for VOSviewer and CiteSpace analyses. Inclusion and extraction criteria The inclusion criteria comprised original research articles published in English between 2016 and 2025, focusing on graphene and its derivatives in the context of cancer, tumor, neoplasm, or malignancy. Only peer-reviewed articles were considered. The exclusion criteria eliminated non-article document types (e.g., reviews, conference papers), non-English publications, and articles outside the defined time frame. Data were extracted from Scopus using the Title-Abstract-Keyword fields and exported in multiple formats to support analysis in bibliometric software tools. Analysis To conduct a comprehensive bibliometric evaluation of graphene-based nanomaterials in cancer research from 2016 to 2025, data were extracted from the Scopus database and analyzed using a combination of advanced bibliometric software tools. Three principal platforms were employed to ensure a multifaceted analysis: VOSviewer (version 1.6.19, Centre for Science and Technology Studies, Leiden University, Leiden, The Netherlands), CiteSpace (version 6.2.R6, Drexel University, Philadelphia, PA, USA), and the Bibliometrix R package (version 4.2.1, University of Naples Federico II, Naples, Italy) [22–24]. The research growth trend was explored through annual publication output and citation metrics, highlighting the evolution of scholarly attention in the domain. The productivity and citation impact of leading nations was mapped to illustrate their dominant contributions and global research clusters. Citation velocity metrics were calculated as the mean number of citations per article normalized by the number of years since publication, providing a dynamic measure of annual citation accrual. Author productivity and influence was measured through co-authorship and citation metrics, while publication cores were ranked according to core source citation counts based on Bradford’s Law [22]. International collaboration networks were visualized using VOSviewer, where node sizes represented country output and link strength indicated the intensity of partnerships. The diffusion of knowledge was analyzed through total link strength and citation density. In VOSviewer, Total Link Strength (TLS) is the sum of the link strengths between an item (like an author or keyword) and all the other items it is connected to in the network, indicating its overall connectivity and importance. Author keywords were examined for frequency and co-occurrence patterns, providing insight into the thematic orientation and research priorities over time [24]. A threshold of seven publications for institutions and thirty occurrences for keywords was applied to balance analytical clarity with interpretability, following practices adopted in prior bibliometric studies, while recognizing that alternative thresholds may yield complementary insights. Conceptual mapping and thematic evolution were conducted using Bibliometrix [22], was used for conceptual mapping alongside thematic evolution to uncover motor themes, niche areas, as well as developed and developing trajectories. CiteSpace was used for Reference Co-Citation Analysis (RCA), burst detection, and timeline visualizations to trace influential references and evolving research fronts [23]. An overlay visualization plot was generated to track temporal shifts in keyword prominence. Lastly, trigram analysis of emerging phrases allowed deeper semantic insights into novel and recurring conceptual patterns. Collectively, these analytical strategies ensured a robust and multidimensional interpretation of the research landscape. Counting and aggregation methods All bibliometric analyses were performed using full counting, whereby each co-authorship, institutional link, or keyword occurrence was assigned equal weight. Fractional counting was not applied, as the aim was to capture the absolute scale of research contributions. For network analyses, VOSviewer’s default association strength normalization was used to adjust edge weights, and TLS (Total Link Strength) was reported as a measure of connectivity. Self-citations were included, consistent with prior bibliometric mapping practice, but were monitored to ensure they did not disproportionately affect global trends. Threshold justification and sensitivity check To ensure robust mapping, thresholds were applied consistently: authors (≥10 publications), institutions (≥7), and keywords (≥30 occurrences). These criteria (Table S1) balanced inclusivity with interpretability, avoiding excessive fragmentation of networks. A sensitivity check (±20% around each threshold) produced comparable cluster structures and stable dominant themes, confirming that the main results were not materially altered by threshold variation. Results Data overview and research growth The extracted bibliographic dataset comprises 4917 documents published between 2016 and 2025 across 931 sources, with an annual growth rate of 2.97%. The average document age is 4.16 years, and each document has received approximately 29.62 citations. A total of 13,879 authors contributed to the corpus, with only 34 single-authored papers, reflecting a strong trend toward collaborative research, averaging 6.52 co-authors per publication. International collaboration is evident in 26.09% of the documents. The dataset includes 23,274 Indexed Keywords and 9507 author-defined keywords, indicating rich thematic diversity within graphene and cancer-related research. Figure 2 illustrates the annual publication and citation trends in graphene and cancer research from 2016 to 2025. The number of articles steadily increased, peaking at 600 publications in 2024, indicating rising research interest. The mean citations per article (MeanTCperArt) exhibited a clear declining trend across the study period. Early publications achieved relatively high citation averages, peaking at 62.28 citations per article, while subsequent years showed a progressive decrease: 47.27, 48.08, 36.39, and 28.68, eventually falling to 19.75 and 13.50. The most recent years reflected the lowest averages, with 5.88 and 1.43 citations per article, respectively. This temporal decline reflects the well-established phenomenon of citation lag, where newly published works have not yet had sufficient time to accrue citations compared to earlier studies. As 2025 is a partial year, the observed counts for this year are incomplete and should be interpreted with caution when comparing with full-year data. The data highlight a temporal shift in scholarly impact and research dissemination within the field.Fig. 2A Growth and citation analysis of research in graphene and cancer (2016–2025). This Figure shows annual publication growth and citation trends. Blue bars represent the number of articles, which steadily increased over time. The line illustrates mean citations per article, which declined from 2017 onward, indicating reduced citation accumulation in recent years due to publication recency and citation lag effects. Note: Data for 2025 represent a partial year and may not reflect complete publication or citation trends. B Citation velocity metrics for graphene-based cancer research (2016–2025). Values reflect the average number of citations accrued per paper per year since publication. Peak citation velocity was observed in 2019 (6.87), followed by gradual decline, reflecting citation lag for recently published articles A Growth and citation analysis of research in graphene and cancer (2016–2025). This Figure shows annual publication growth and citation trends. Blue bars represent the number of articles, which steadily increased over time. The line illustrates mean citations per article, which declined from 2017 onward, indicating reduced citation accumulation in recent years due to publication recency and citation lag effects. Note: Data for 2025 represent a partial year and may not reflect complete publication or citation trends. B Citation velocity metrics for graphene-based cancer research (2016–2025). Values reflect the average number of citations accrued per paper per year since publication. Peak citation velocity was observed in 2019 (6.87), followed by gradual decline, reflecting citation lag for recently published articles Figure 2B presents the citation velocity metrics, expressed as the average number of citations accrued per paper per year since publication. The data show that articles published between 2016 and 2020 sustained the highest citation velocity, ranging from 5.73 (2016) to 6.87 (2019). The peak was observed in 2019, with each article receiving on average 6.87 citations annually. Publications from 2021 maintained a comparable rate (5.74), but a gradual decline followed from 2022 (4.94) to 2023 (4.50). A more pronounced drop occurred for recent cohorts, with values of 2.94 in 2024 and 1.43 in 2025, consistent with the expected citation lag effect in newly published work. These results indicate that while the field achieved strong citation momentum during 2016–2020, more recent contributions have not yet had sufficient time to accumulate comparable scholarly impact. Leading nations: productivity, collaboration and citation mapping The global research landscape on graphene and cancer from 2016 to 2025 demonstrates a clear dominance by China in both publication output and citation impact. China contributed 2160 publications and received a remarkable 74,197 citations, reflecting its leadership and central role in advancing this research field. India (706 documents), Iran (664), and the United States (431) follow as major contributors, with Iran and the U.S. also achieving substantial citation counts of 19,909 and 18,448, respectively. South Korea, Saudi Arabia, Taiwan, and the United Kingdom made notable contributions, each exceeding 100 publications. In terms of impact, countries such as Taiwan (6,089 citations), Saudi Arabia (4850), and Australia (4233) also emerged as significant players. Figure 3A, generated using Bibliometrix, displays the global productivity distribution where darker blue shades represent higher output. To further illustrate geographical disparities, country-level productivity for underrepresented regions (Africa, Latin America, and parts of Europe) is provided in Table S2.Fig. 3Global Contribution, Collaboration and Citation Impact in graphene-based cancer research (2016–2025). A World map visualization of country-level publication output, where darker shades of blue indicate higher research productivity. This map was generated using Bibliometrix (R-package) based on bibliographic data extracted from Scopus. B Global country collaboration map (2016–2025) in graphene-based cancer research. Darker shading indicates higher productivity, while connecting lines represent co-authorship links. Line thickness reflects collaboration strength, highlighting China–USA, India–Saudi Arabia, and China–India as leading international research partnerships. C Citation density visualization of countries with ≥5 publications in graphene-based cancer research (2016–2025). Halo intensity represents citation frequency, with additional labels provided for clarity. Contrasting outlines highlight major hubs to ensure accessibility for color-blind readers. Data source: Scopus; visualization created using VOSviewer v1.6.19 (Leiden University, Netherlands) Global Contribution, Collaboration and Citation Impact in graphene-based cancer research (2016–2025). A World map visualization of country-level publication output, where darker shades of blue indicate higher research productivity. This map was generated using Bibliometrix (R-package) based on bibliographic data extracted from Scopus. B Global country collaboration map (2016–2025) in graphene-based cancer research. Darker shading indicates higher productivity, while connecting lines represent co-authorship links. Line thickness reflects collaboration strength, highlighting China–USA, India–Saudi Arabia, and China–India as leading international research partnerships. C Citation density visualization of countries with ≥5 publications in graphene-based cancer research (2016–2025). Halo intensity represents citation frequency, with additional labels provided for clarity. Contrasting outlines highlight major hubs to ensure accessibility for color-blind readers. Data source: Scopus; visualization created using VOSviewer v1.6.19 (Leiden University, Netherlands) Figure 3B illustrates the global collaboration landscape. The connecting lines indicate co-authorship links, where line thickness reflects collaboration intensity. The strongest bilateral partnerships were observed between China–USA (146 co-authored papers), India–Saudi Arabia (100), China–India (62), and China–UK (55). Other notable ties include India–Korea (48), Iran–USA (48), and Saudi Arabia–Egypt (36), underscoring the emergence of regional and cross-continental networks. China additionally exhibited strong collaborations with Australia (40), Saudi Arabia (38), and Hong Kong (28), confirming its pivotal role as a global research connector. Overall, the map emphasizes the dense interconnectivity among Asia, North America, and Europe, while also revealing the growing visibility of Middle Eastern and African collaborations. Figure 3C, produced via VOSviewer, provides a citation density heatmap where halo intensity corresponds to citation frequency, highlighting China, the U.S., and Iran as key hubs. These patterns reflect not only the quantitative dominance of select nations but also their growing international collaboration and influence in shaping the trajectory of graphene-based cancer research. Author impact analysis Table 1 presents the productivity and impact metrics of leading authors in graphene-based cancer research as indexed in Scopus. Among the most influential contributors, Bianco, A. (France) and Wei, Q. (South Korea) achieved exceptionally high citation impact, with total citations exceeding 43,000 and 40,000, respectively, coupled with H-indices of 88 and 94, reflecting sustained influence in the field. Namazi, H. (Iran) and Hasanzadeh, M. (Iran) also demonstrated strong scholarly output, with H-indices of 63 and 60 and citation counts above 10,000. Regional leaders such as Pourmadadi, M., Yazdian, F., and Hou, C. showed balanced productivity (≥20 publications) with high citation impact, underscoring their central roles in advancing graphene applications in oncology. Collectively, these results highlight both global distribution and regional hubs of expertise, particularly across Iran, China, and South Korea.Table 1Author productivity and impact metricsAuthorScopus IDInstitutionH-IndexTCNPPourmadadi, M57205730411Shahid Beheshti University, Tehran, Iran46582332Ilie-Mihai, R.M57203986386National Institute of Research for Electrochemistry and Condensed Matter, Bucharest1027025Namazi, H6602623076University of Tabriz, Tabriz, Iran6310,50725Yazdian, F25648725600University of Tehran, Tehran, Iran48692224Wei, Q7201692981Sungkyunkwan University, Seoul, South Korea9440,06623Bianco, A7203002764Laboratoire d’Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT) Strasbourg, France8843,62121Stefan-van Staden, R.I6505677090National Institute of Research for Electrochemistry and Condensed Matter, Bucharest32490821Hou, C18634044800Chongqing University, Chongqing, China5412,25520Huo, D12777960000Chongqing University, Chongqing, China5110,42520Hasanzadeh, M6507104474Tabriz University of Medical Sciences, Tabriz, Iran6012,68519H-Index measures productivity and citation impact, TC is total citations, NP is number of publications, PY-start is the first publication year Table 1Author productivity and impact metricsAuthorScopus IDInstitutionH-IndexTCNPPourmadadi, M57205730411Shahid Beheshti University, Tehran, Iran46582332Ilie-Mihai, R.M57203986386National Institute of Research for Electrochemistry and Condensed Matter, Bucharest1027025Namazi, H6602623076University of Tabriz, Tabriz, Iran6310,50725Yazdian, F25648725600University of Tehran, Tehran, Iran48692224Wei, Q7201692981Sungkyunkwan University, Seoul, South Korea9440,06623Bianco, A7203002764Laboratoire d’Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT) Strasbourg, France8843,62121Stefan-van Staden, R.I6505677090National Institute of Research for Electrochemistry and Condensed Matter, Bucharest32490821Hou, C18634044800Chongqing University, Chongqing, China5412,25520Huo, D12777960000Chongqing University, Chongqing, China5110,42520Hasanzadeh, M6507104474Tabriz University of Medical Sciences, Tabriz, Iran6012,68519H-Index measures productivity and citation impact, TC is total citations, NP is number of publications, PY-start is the first publication year Author productivity and impact metrics H-Index measures productivity and citation impact, TC is total citations, NP is number of publications, PY-start is the first publication year Leading sources: Bradford’s Law Bradford’s Law partitioned the 931 sources publishing on graphene and cancer into three productivity zones. Zone 1 (core zone) includes 21 journals contributing the highest number of articles (e.g., Biosensors and Bioelectronics, ACS Applied Materials and Interfaces, and RSC Advances), representing the most influential sources. Zone 2 comprises 84 journals with moderate productivity, while Zone 3 includes 826 low-output sources. The core journals alone account for a disproportionately large share of publications, confirming Bradford’s prediction that few sources dominate scholarly output. The logarithmic curve in Fig. 4 visually highlights this steep productivity decline across zones. As illustrated in Fig. 4, the identification of 21 core journals through Bradford’s Law highlights the concentration of high-impact work in a limited set of sources, underscoring the importance of these journals for researchers seeking visibility and for institutions developing publication strategies. Table S3 summarizes the 2024 Journal Impact Factors (JIF) and quartiles based on data from Clarivate Analytics.Fig. 4Bradford’s Law Analysis of Source Distribution in Graphene and Cancer Research (2016–2025). The core journals alone account for a disproportionately large share of publications, confirming Bradford’s prediction that few sources dominate scholarly output Bradford’s Law Analysis of Source Distribution in Graphene and Cancer Research (2016–2025). The core journals alone account for a disproportionately large share of publications, confirming Bradford’s prediction that few sources dominate scholarly output Collaboration networks The co-authorship and institutional collaboration analyses presented in Fig. 5 provide a comprehensive overview of the collaborative landscape in raphene-based cancer research. At the author level (Fig. 5A), 117 authors met the threshold of publishing at least 10 documents, forming 36 distinct clusters with 175 collaboration links and a total link strength (TLS) of 1038. Among the most central authors based on TLS were Sawosz Ewa (TLS = 61), Wierzbicki Mateusz (TLS = 59), and Pourmadadi Mehrab (TLS = 58), indicating their prominent roles in fostering co-authorship networks and academic influence within this research domain. At the organizational level (Fig. 5B), 52 institutions met the inclusion criterion (minimum of 7 publications), resulting in 32 clusters and a total TLS of 123. The most interconnected organizations included the Department of Life Science Engineering, University of Tehran (TLS = 23) and the Drug Applied Research Center, Tabriz University of Medical Sciences (TLS = 21). Notably, several Iranian research centers featured prominently, reflecting a strong national collaboration network. At the country level (Fig. 5C), 66 countries formed 8 collaboration clusters, linked by 661 total connections and a TLS of 2545. China (TLS = 576), India (TLS = 450), and the United States (TLS = 424) emerged as global leaders in international research cooperation. Saudi Arabia also demonstrated substantial engagement (TLS = 347), indicating its growing influence in the field. The strong interconnectivity among Asian, North American, and European countries underscores the global nature of raphene-based cancer research and the importance of cross-border scientific collaboration. Overall, the findings suggest that productive co-authorship networks are driven by both individual researchers and institutions, with China playing a dominant role globally. These insights are valuable for identifying potential collaborators and understanding the structural dynamics of scientific production in this rapidly evolving research area.Fig. 5Collaboration Networks in Raphene-based cancer research. This multi-panel visualization illustrates collaboration networks among authors (A), organizations (B), and countries (C) based on co-authorship analysis. The data were retrieved from the Scopus database and analyzed using VOSviewer. In VOSviewer, Total Link Strength (TLS) is the sum of the link strengths between an item (like an author or keyword) and all the other items it is connected to in the network, indicating its overall connectivity and importance Collaboration Networks in Raphene-based cancer research. This multi-panel visualization illustrates collaboration networks among authors (A), organizations (B), and countries (C) based on co-authorship analysis. The data were retrieved from the Scopus database and analyzed using VOSviewer. In VOSviewer, Total Link Strength (TLS) is the sum of the link strengths between an item (like an author or keyword) and all the other items it is connected to in the network, indicating its overall connectivity and importance Diffusion of knowledge The bar chart in Fig. 6 showcases the diverse disciplinary footprint of raphene-based cancer research, reflecting its inherently interdisciplinary nature. Dominated by Chemistry (20.31%), Materials Science (17.50%), and Engineering (13.57%), the field is firmly rooted in the physical sciences and nanotechnology. Notably, substantial contributions from Biochemistry, Genetics and Molecular Biology (13.11%), Chemical Engineering (10.01%), and Physics and Astronomy (7.99%) underscore the field’s molecular and structural underpinnings. The presence of biomedical disciplines—such as Pharmacology, Toxicology, Pharmaceutics (5.56%) and Medicine (4.45%)—points to translational efforts bridging lab-based innovations with clinical applications. Although peripheral fields like Environmental Science, Computer Science, and Multidisciplinary studies contribute modestly, areas such as Social Sciences, Psychology, and Veterinary Science show only minimal engagement. This pattern suggests opportunities for further interdisciplinary expansion, particularly in addressing societal, ecological, and patient-centered dimensions of graphene-based cancer research.Fig. 6Diffusion of knowledge in raphene-based cancer research across subject areas. Data were categorized by subject percentage from Scopus Diffusion of knowledge in raphene-based cancer research across subject areas. Data were categorized by subject percentage from Scopus Density and frequency patterns of author keywords The keyword analysis presented in Fig. 7 provides a comprehensive overview of the thematic structure of graphene and cancer research. Figure 7A displays the density visualization based on keyword occurrences, where “graphene oxide” (811 occurrences) and “graphene” (419 occurrences) emerge as the most dominant terms, indicating their central role in the research domain. Figure 7B, which is based on total link strength (TLS), highlights the strongest co-occurrence relationships. “Graphene oxide” again leads (TLS = 791), followed by “graphene,” “drug delivery,” and “photothermal therapy,” reflecting the high interconnectivity of these themes in the literature. Figure 7C presents a normalized word cloud emphasizing frequent and impactful keywords such as “human,” “nanoparticles,” “diseases,” “photothermal therapy,” “biosensor,” and “cancer,” further confirming the relevance of these terms. Notably, keywords such as “doxorubicin,” “apoptosis,” and “cytotoxicity” suggest a strong focus on drug response and cancer cell biology. Overall, the keyword analysis, based on a threshold of a minimum of 30 keyword occurrences (55 keywords met this threshold out of 9493), was generated using VOSviewer and reflects the convergence of nanotechnology, drug delivery, cancer therapeutics, and biosensing techniques within the graphene research landscape. Table S4 detailed the top 50 keywords and its TLS values.Fig. 7Keyword analysis of graphene-based cancer research using VOSviewer. A Density visualization of authors’ keywords based on occurrence (≥30). Frequently used terms such as “graphene oxide” and “graphene” are highlighted with bold labels, while contrasting outlines improve accessibility for color-blind readers. Node intensity reflects frequency of occurrence. Visualization created using VOSviewer v1.6.19 (Leiden University, Netherlands).” B Density map based on total link strength (TLS), showing co-occurrence strength among terms. In VOSviewer, Total Link Strength (TLS) is the sum of the link strengths between an item (like an author or keyword) and all the other items it is connected to in the network, indicating its overall connectivity and importance. C Normalized word cloud visualizing key themes and term prominence. The analysis was performed using VOSviewer v1.6.19 (Leiden University, Netherlands) based on 55 keywords with a minimum occurrence threshold of 30. Data source: Scopus database Keyword analysis of graphene-based cancer research using VOSviewer. A Density visualization of authors’ keywords based on occurrence (≥30). Frequently used terms such as “graphene oxide” and “graphene” are highlighted with bold labels, while contrasting outlines improve accessibility for color-blind readers. Node intensity reflects frequency of occurrence. Visualization created using VOSviewer v1.6.19 (Leiden University, Netherlands).” B Density map based on total link strength (TLS), showing co-occurrence strength among terms. In VOSviewer, Total Link Strength (TLS) is the sum of the link strengths between an item (like an author or keyword) and all the other items it is connected to in the network, indicating its overall connectivity and importance. C Normalized word cloud visualizing key themes and term prominence. The analysis was performed using VOSviewer v1.6.19 (Leiden University, Netherlands) based on 55 keywords with a minimum occurrence threshold of 30. Data source: Scopus database Thematic evolution and research transition Thematic evolution analysis (Fig. 8A) highlights the transition in research focus from earlier themes such as “biosensor” and “graphene oxide” (2016–2021) to emerging and specialized domains between 2022 and 2025. Early biosensor research evolved into electrochemical immunosensors and electroluminescent techniques applied to breast cancer detection and biomarker identification. Simultaneously, foundational graphene oxide studies progressed into targeted cancer therapies involving graphene quantum dots, photothermal therapy, and nanocarriers. Figure 8B classifies “biosensor” as a niche theme, while “graphene” and “drug delivery” appear as basic, enduring research themes. Figure 8C identifies current motor themes—such as immunosensors and nanotechnology—signaling high centrality and development, reflecting future research trajectories.Fig. 8Thematic evolution and mapping of research trends in graphene-based cancer studies. A Thematic evolution from 2016–2021 to 2022–2025, highlighting progression from “biosensor” and “graphene oxide” to advanced themes such as “electrochemical immunosensor” and “breast cancer.” B Thematic map (2016–2021) classifying themes by centrality and density. C Thematic map (2022–2025) showing more refined clusters with emerging, niche, and motor themes. Analysis was conducted using Bibliometrix R-package (version 4.2.0) based on Scopus data. Quadrants reflect theme relevance and development level Thematic evolution and mapping of research trends in graphene-based cancer studies. A Thematic evolution from 2016–2021 to 2022–2025, highlighting progression from “biosensor” and “graphene oxide” to advanced themes such as “electrochemical immunosensor” and “breast cancer.” B Thematic map (2016–2021) classifying themes by centrality and density. C Thematic map (2022–2025) showing more refined clusters with emerging, niche, and motor themes. Analysis was conducted using Bibliometrix R-package (version 4.2.0) based on Scopus data. Quadrants reflect theme relevance and development level Thematic structure and conceptual mapping To analyze the conceptual structure of graphene-related cancer research, a supervised thematic map analysis was performed using the Bibliometrix application (Fig. 9). Author’s keywords were clustered based on co-occurrence using the “Leading Eigenvalues” algorithm, with parameters set to 500 words, 5 minimum frequency per 1000 documents, and a label size of 0.3. This yielded three key themes: “graphene oxide,” “graphene,” and “reduced graphene oxide.” These were plotted by Callon centrality (relevance) and Callon density (development). “Reduced graphene oxide” exhibited the highest density (3.432) but the lowest centrality (0.067), suggesting it is a specialized yet under-integrated theme. Conversely, “graphene oxide” had higher centrality (0.128), indicating its foundational role in this research domain. These positions help distinguish between emerging, niche, and basic themes and provide insight into the thematic development of the field.Fig. 9Thematic Map of Raphene-based cancer research Based on Author Keywords. This strategic diagram categorizes themes by centrality (relevance) and density (development). Motor themes—graphene oxide, drug delivery, and graphene quantum dots—are both well-developed and highly connected. Niche themes, such as reduced graphene oxide and electrochemical immunosensors, are well-developed but less connected. Graphene, cancer, and biosensor appear as basic themes, indicating foundational but less specialized areas. Author’s keywords were clustered based on co-occurrence using the “Leading Eigenvalues” algorithm, with parameters set to 500 words, 5 minimum frequency per 1000 documents, and a label size of 0.3 Thematic Map of Raphene-based cancer research Based on Author Keywords. This strategic diagram categorizes themes by centrality (relevance) and density (development). Motor themes—graphene oxide, drug delivery, and graphene quantum dots—are both well-developed and highly connected. Niche themes, such as reduced graphene oxide and electrochemical immunosensors, are well-developed but less connected. Graphene, cancer, and biosensor appear as basic themes, indicating foundational but less specialized areas. Author’s keywords were clustered based on co-occurrence using the “Leading Eigenvalues” algorithm, with parameters set to 500 words, 5 minimum frequency per 1000 documents, and a label size of 0.3 Reference co-citation analysis (RCA) Reference co-citation analysis (RCA) is a pivotal technique in bibliometric mapping used to uncover the conceptual structure of a research field. It measures how frequently two documents are cited together in subsequent literature, indicating their conceptual or methodological relatedness. In this study, RCA was applied using CiteSpace to analyze 4917 articles on graphene and cancer (2016–2025), revealing 16 major thematic clusters (Fig. 10A–C; Table 2). The largest cluster (#0, “graphene oxide”) included foundational works on drug delivery and imaging, while Cluster #1 (“carcinoembryonic antigen”) focused on biosensing and cancer diagnostics. Other significant clusters include #2 “hydrophilic drug,” #4 “drug delivery application,” and #6 “brain cancer treatment.” The clusters varied in average publication year, size, and silhouette value, reflecting both thematic cohesion and temporal evolution. Citation-based metrics such as global citation score and citation bursts, as well as network metrics like betweenness and degree centrality, highlighted influential publications within each cluster. Figure 10B visualizes the density and strength of co-citation networks, while Fig. 10C provides a temporal view of cluster emergence and development. The analysis underscores the evolution of graphene-based cancer research, highlighting both established themes and emerging directions such as nanohybrids, pharmaceutical formulations, and colorectal cancer biomarkers. The full CiteSpace clustering output, including modularity, silhouette values, and detailed node/edge information, is provided as Supplementary File 1.Fig. 10Reference Co-Citation Analysis (RCA) of Graphene and Cancer Research (2016–2025). A Co-citation network showing 16 color-coded clusters, with node size indicating citation frequency and edge thickness representing co-citation strength. B Cluster visualization colored by average publication year, illustrating the temporal distribution of themes, with purple being most recent. C Timeline view of clusters highlighting the evolution of key topics. Larger nodes reflect citation bursts. Cluster labels in all panels correspond to major thematic areas, such as graphene oxide (#0) and drug delivery applications (#4)Table 2Reference co-citation analysis (RCA)Cluster IDSizeSilhouetteLabel (LSI)Label (LLR)Label (MI)Average year01270.892Superparamagnetic reduced graphene oxideGraphene oxide (398.97, 1.0E−4)Combination treatment (2.89)20121850.916Cancer treatmentCarcinoembryonic antigen (526.41, 1.0E−4)Using methylene blue (1.2)20202620.82Polydopamine-functionalized nanographene oxideHydrophilic drug (206.18, 1.0E−4)Vivo evaluation (0.94)20143610.927Microfluidic paper-based analytical deviceSpecific antigen (774.85, 1.0E−4)Quantitative detection (0.48)20164530.926Tumor-associated macrophageDrug delivery application (264.16, 1.0E−4)Monodispersed magnetographene quantum (0.47)20175480.92Enhancing cancer radioisotope therapyVersatile supramolecule (212.42, 1.0E−4)Electrical response (0.81)20176470.917Graphene oxideBrain cancer treatment (245.11, 1.0E−4)Applying cancer antigen_125 biomarkers detection (0.14)20218430.913Targeted cancer therapyGraphene quantum (255.43, 1.0E−4)Peptide-influenced graphene quantum dot (0.27)20139330.829Graphene compositePlasmonic nanohybrid (332.53, 1.0E−4)Graphene composite (0.25)201610280.876Graphene oxideHuman acute monocytic leukemia cell line (169.48, 1.0E−4)Absorbing chlorin (0.12)201512170.973Graphene oxideColorectal cancer biomarker (57.95, 1.0E−4)Graphene oxide (0.04)202113161ElectrodeSuperior electrocatalytic activity (30.53, 1.0E−4)Graphene oxide (0.04)201714150.935Zif-8 nanoparticlePalladium nanoparticle (126.28, 1.0E−4)Combination treatment (0.04)20191590.997Blocking geneEffective drug delivery system (83.51, 1.0E−4)Graphene oxide (0.03)20191690.995Carcinoembryonic antigenMxene-graphene nanohybrid thin film (65.78, 1.0E−4)Graphene oxide (0.04)20201760.992Photodynamic therapyPharmaceutical formulation (57.67, 1.0E−4)Graphene oxide (0.04)2020 Reference Co-Citation Analysis (RCA) of Graphene and Cancer Research (2016–2025). A Co-citation network showing 16 color-coded clusters, with node size indicating citation frequency and edge thickness representing co-citation strength. B Cluster visualization colored by average publication year, illustrating the temporal distribution of themes, with purple being most recent. C Timeline view of clusters highlighting the evolution of key topics. Larger nodes reflect citation bursts. Cluster labels in all panels correspond to major thematic areas, such as graphene oxide (#0) and drug delivery applications (#4) Table 2Reference co-citation analysis (RCA)Cluster IDSizeSilhouetteLabel (LSI)Label (LLR)Label (MI)Average year01270.892Superparamagnetic reduced graphene oxideGraphene oxide (398.97, 1.0E−4)Combination treatment (2.89)20121850.916Cancer treatmentCarcinoembryonic antigen (526.41, 1.0E−4)Using methylene blue (1.2)20202620.82Polydopamine-functionalized nanographene oxideHydrophilic drug (206.18, 1.0E−4)Vivo evaluation (0.94)20143610.927Microfluidic paper-based analytical deviceSpecific antigen (774.85, 1.0E−4)Quantitative detection (0.48)20164530.926Tumor-associated macrophageDrug delivery application (264.16, 1.0E−4)Monodispersed magnetographene quantum (0.47)20175480.92Enhancing cancer radioisotope therapyVersatile supramolecule (212.42, 1.0E−4)Electrical response (0.81)20176470.917Graphene oxideBrain cancer treatment (245.11, 1.0E−4)Applying cancer antigen_125 biomarkers detection (0.14)20218430.913Targeted cancer therapyGraphene quantum (255.43, 1.0E−4)Peptide-influenced graphene quantum dot (0.27)20139330.829Graphene compositePlasmonic nanohybrid (332.53, 1.0E−4)Graphene composite (0.25)201610280.876Graphene oxideHuman acute monocytic leukemia cell line (169.48, 1.0E−4)Absorbing chlorin (0.12)201512170.973Graphene oxideColorectal cancer biomarker (57.95, 1.0E−4)Graphene oxide (0.04)202113161ElectrodeSuperior electrocatalytic activity (30.53, 1.0E−4)Graphene oxide (0.04)201714150.935Zif-8 nanoparticlePalladium nanoparticle (126.28, 1.0E−4)Combination treatment (0.04)20191590.997Blocking geneEffective drug delivery system (83.51, 1.0E−4)Graphene oxide (0.03)20191690.995Carcinoembryonic antigenMxene-graphene nanohybrid thin film (65.78, 1.0E−4)Graphene oxide (0.04)20201760.992Photodynamic therapyPharmaceutical formulation (57.67, 1.0E−4)Graphene oxide (0.04)2020 Reference co-citation analysis (RCA) Overlay visualization Figure 11 presents an overlay visualization of authors’ keywords in raphene-based cancer research, using VOSviewer. Keywords are color-coded by average publication year, with yellow nodes indicating more recent topics. The central dominance of terms like "graphene oxide" and "photodynamic therapy" reflects foundational research. Emerging trends, shown in yellow, include “refractive index sensor,” “Terahertz,” “optical sensor,” “surface plasmon resonance,” “aptasensor,” and “chemodynamic therapy.” These indicate a shift toward advanced diagnostic and biosensing technologies. The appearance of terms like “label-free immunosensor” and “cancer cell detection” suggests an evolving focus on precision oncology and non-invasive therapeutic monitoring using graphene-based platforms.Fig. 11Overlay visualization of authors’ keywords in raphene-based cancer research generated using VOSviewer. The color gradient represents the average publication year of each keyword, ranging from 2020 (blue) to 2023 (yellow). Yellow-colored nodes denote more recent and emerging topics, indicating growing interest in innovative areas such as biosensing, terahertz technology, and label-free immunosensors Overlay visualization of authors’ keywords in raphene-based cancer research generated using VOSviewer. The color gradient represents the average publication year of each keyword, ranging from 2020 (blue) to 2023 (yellow). Yellow-colored nodes denote more recent and emerging topics, indicating growing interest in innovative areas such as biosensing, terahertz technology, and label-free immunosensors Trigram analysis of emerging themes The bubble plot (Fig. 12) generated using Bibliometrix illustrates trigram analysis of emerging topics in raphene-based cancer research, focusing on terms in article titles. Each horizontal line represents a trigram’s active period, showing the timeline of its usage. The circles represent the frequency of appearance, with larger bubbles indicating higher term frequency. For example, “plasmon resonance biosensor,” “brain tumor detection,” and “breast cancer detection” have recently emerged and are gaining prominence. The right-shifted placement of terms such as “graphene oxide nanoparticles” and “surface plasmon resonance” highlights their recent surge in scholarly attention, marking them as contemporary hotspots in graphene-based cancer research.Fig. 12Trend Topics in Raphene-based cancer research. This bubble chart shows the evolution over time of trending trigrams in the titles of research articles on graphene and cancer. The horizontal lines show the active publication span of each term, while bubbles are sized according to the term’s frequency. Notable examples include the larger, right-shifted bubbles “plasmon resonance biosensor” and “brain tumor detection”—both indicative of emerging, high-impact themes gaining prominence during the most recent years (2023–2025). Bubble chart of emerging trigrams in article titles (2016–2025), generated with Bibliometrix (R-package, Naples, Italy). Bubble size indicates frequency of occurrence, while horizontal placement reflects the time of first appearance. Right-shifted, larger bubbles (e.g., “plasmon resonance biosensor,” “brain tumor detection”) mark the most recent emerging topics Trend Topics in Raphene-based cancer research. This bubble chart shows the evolution over time of trending trigrams in the titles of research articles on graphene and cancer. The horizontal lines show the active publication span of each term, while bubbles are sized according to the term’s frequency. Notable examples include the larger, right-shifted bubbles “plasmon resonance biosensor” and “brain tumor detection”—both indicative of emerging, high-impact themes gaining prominence during the most recent years (2023–2025). Bubble chart of emerging trigrams in article titles (2016–2025), generated with Bibliometrix (R-package, Naples, Italy). Bubble size indicates frequency of occurrence, while horizontal placement reflects the time of first appearance. Right-shifted, larger bubbles (e.g., “plasmon resonance biosensor,” “brain tumor detection”) mark the most recent emerging topics Discussion The past ten years have seen an explosion of interest in graphene-based cancer research due to the growth of new fields like nanotechnology, biomedical engineering, and interdisciplinary collaborations. This study sought to analyze the vast body of literature on graphene and performed a detailed bibliometric analysis on its structure, themes, and evolution. Using VOSviewer, CiteSpace, and Bibliometrix, the study maps author productivity, institutional collaboration, co-citation networks, and keyword clusters. Similar integrative approaches have been employed in mapping emerging technologies such as quantum computing and 4D printing, where overlay visualization and thematic mapping have proven effective for capturing dynamic research frontiers [25, 26]. The novelty of the present study lies in its holistic and multidimensional bibliometric evaluation of graphene-based nanomaterials in cancer research, covering a broader timeframe (2016–2025) and incorporating advanced analytical dimensions that address key gaps in prior works. While previous studies, such as Zhang et al. (2023) and Barba-Rosado et al. (2024), focused narrowly on specific cancers like breast or bone cancer or limited therapeutic modalities such as photothermal therapy, our analysis captures the entire research ecosystem—encompassing diagnostics, therapy, biosensors, immunosensors, and emerging photonic technologies [14, 15]. Unlike Wu et al. [17], which concentrated on toxicity, or Zhan et al. [27], which explored graphene oxide broadly, this study uniquely centers on its application in oncology, contextualized within evolving scientific themes, collaboration patterns, and citation dynamics. Moreover, while Freitas et al. [28] and Hou et al. [16] emphasized synthesis and nanovaccine trends respectively, they did not map the thematic evolution or conceptual transitions within the oncology context. Our work advances the field by employing integrative tools (VOSviewer, CiteSpace, Bibliometrix) to triangulate co-authorship, keyword density, reference co-citation, and trigram evolution—providing the first comprehensive overlay of research transition and thematic motor zones in graphene based-cancer scholarship. This approach not only fills a methodological and topical gap but also provides actionable insights for future translational and collaborative research. The nearly decade-long upward trajectory in publications—from under 350 in 2016 to a peak of 600 in 2024—mirrors broader bibliometric trends observed across fast-evolving fields such as graphene-enabled cancer nanomedicine, where intensified interest corresponds with technological advances and increased research funding [14, 29, 30]. However, the sharp decline in mean citations per article, from 62.3 in 2017 to just 1.4 in 2025, is emblematic of a classical "citation lag" effect, where freshly published works have not yet had time to be incorporated into subsequent research [18, 31]. This pattern complicates evaluations of scholarly impact based purely on citation counts and suggests that traditional bibliometric indicators may undervalue emerging research fronts. For the graphene-based cancer research domain, this implies that recent methodological breakthroughs—such as graphene quantum dot-based immunosensing—are gaining visibility [32] but have yet to accrue citations commensurate with their scientific potential. This pattern complicates evaluations of scholarly impact based purely on citation counts and suggests that traditional bibliometric indicators may undervalue emerging research fronts [33]. For the graphene–cancer domain, this implies that recent methodological breakthroughs—such as graphene quantum dot-based immunosensing—are gaining visibility but have yet to accrue citations commensurate with their scientific potential. The observed dynamics underscore a maturing research ecosystem: one that is expanding access (in terms of increasing publication volume) while awaiting critical validation through citations. To more accurately assess impact in emergent areas, incorporation of early metrics—such as citation velocity, altmetrics, or expert peer evaluation—may be prudent. Additionally, longitudinal tracking of citation accrual across defined cohorts could better elucidate when innovative graphene-based studies transition from emerging to established influence. The robust co-authorship and institutional collaboration patterns identified in Fig. 5 reflect a highly interconnected and rapidly evolving research field. The central roles of authors like Sawosz Ewa, Wierzbicki Mateusz, and Pourmadadi Mehrab, and institutions such as the University of Tehran and Tabriz University of Medical Sciences, underscore the impact of individual leadership and national hubs in driving innovation—particularly within Iran and broader Asia. Notably, China’s preeminence at the country level aligns with broader trends in graphene and nanotechnology, where China has consistently assumed a dominant role in publication output and international collaborations [34].This mirrors similar patterns observed in other nanomedicine domains, including hepatocellular carcinoma, where Chinese institutions often lead thematic clusters [35]. These dense networks of collaboration enhance the capacity for resource sharing, interdisciplinary integration, and rapid knowledge diffusion. They are particularly relevant in a field requiring convergence across chemistry, biology, physics, and engineering. However, dominance by specific countries and institutions may also lead to regional imbalances; underrepresentation from Africa, Latin America, and parts of Europe could limit the global diversity of perspectives and impede equitable research progress. Future efforts should therefore foster broader international engagement, including collaborative funding mechanisms and multi-center projects. Emphasizing interdisciplinary linkages—especially with clinicians, regulatory bodies, and industry—can facilitate the translation of graphene-based innovations into clinical and diagnostic applications. As the field progresses, it will be crucial to balance the strengths of existing networks with strategic inclusion of emerging research communities. The disciplinary diversity displayed in Fig. 6 underscores graphene-based cancer research as a deeply interdisciplinary enterprise, weaving together contributions from chemistry, materials science, engineering, and biomedical domains. The predominance of Chemistry (20.3%), Materials Science (17.5%), and Engineering (13.6%) aligns with findings in broader two-dimensional material studies where foundational disciplines drive technological innovation and nanotechnology applications [27]. Crucially, significant input from Biochemistry, Genetics and Molecular Biology (13.1%), and Pharmacology/Toxicology/Pharmaceutics (5.6%) reveals a conscious shift toward translational efforts and clinical relevance, complementing earlier works focused on graphene composites for photothermal and photodynamic therapy [36]. The comparatively modest involvement of fields like Environmental Science or Computer Science, and minimal presence from Social Sciences and Psychology, expose an opportunity to explore graphene’s broader ecological, digital health, and psychosocial dimensions. This disciplinary skew suggests that future research should adopt integrated frameworks—such as eco-toxicological assessments, AI-driven image analytics, or patient-centered outcome studies—to capture the full spectrum of graphene applications in oncology. However, standard subject classifications may oversimplify actual research synergies, and evolving journal indexing practices might distort the assessment of emerging fields. A dynamic reassessment of disciplinary mapping, alongside qualitative data such as research motivations and funding drivers, could enhance understanding of this field’s interdisciplinary evolution. The thematic shift shown in Fig. 8 demonstrates a significant move from basic explorations, such as graphene oxide-based biosensors between 2016 and 2021, to more advanced technologies like electrochemical immunosensors and electroluminescent detection devices from 2022 to 2025. This shift is in line with the global move towards precision diagnostics that are more sensitive and specific in detecting cancer biomarkers, for example, CA 15–3 with graphene quantum dots [37, 38]. At the same time, the development of graphene quantum dots for photothermal and photodynamic therapy evidences expanding fields from diagnostics to therapeutic uses [39–41]. The appearance of “immunosensors” and “nanotechnology” as driving themes, seen in Fig. 8B, C, illustrates the increasing prominence and maturity of these fields. These results indicate a greater degree of thematic consolidation within the research focus, moving from proof-of-concept stages toward clinically applicable platforms. Still, this development is taking place within a rapidly evolving landscape, and interdisciplinary hybrids like graphene-organic frameworks may be understudied due to methodological gaps in the bibliometric approach. In addition, slow citation accumulation may conceal how much emerging technologies will actually contribute in the future. To address these issues, the next research steps should focus on the clinical evaluation of graphene-based immunosensing systems, assessing their translational impact, and analyzing long-term safety profiles. Also, thematic machine learning-based mapping combined with patent analysis could illuminate pathways of innovation. As we move forward, the developing themes illustrate a diagnostic and therapeutic integration, within the field which moving increasingly closer to precision oncology and translational nanomedicine. Several landmark studies shaped the trajectory of graphene-based cancer research. Ebrahimi et al. [8] demonstrated the synergistic efficacy of graphene oxide–doxorubicin conjugates, while Choi et al. [2] and Huang et al. [42] advanced graphene quantum dots in photodynamic and photothermal therapy. Co-citation clusters on biosensing, particularly carcinoembryonic antigen detection, underscore translational relevance. The thematic shift from ‘graphene oxide’ to ‘nanocarriers’ and ‘quantum dots’ reflects graphene’s evolution toward preclinical and diagnostic applications [43]. Such thematic transitions parallel those observed in knowledge domains like artificial intelligence in sustainability and quantum computing, where conceptual landscapes rapidly shift toward translational and application-oriented frontiers [44]. The surge of interest in photodynamic therapy (PDT) within graphene-based cancer research is underscored by recent high-impact studies that showcase significant innovation and therapeutic promise. For example, Gangadharan et al. [45] developed biocompatible, hydrophilic graphitic carbon nitride nanoparticles (g‑CNNPs) capable of efficient reactive oxygen species (ROS) generation under light exposure, demonstrating potent anticancer effects in HT29 cells and validating their potential for clinical PDT applications. Similarly, Gharibzadeh et al. [46] engineered a multifunctional nanocomposite by integrating copper sulfide nanoparticles, graphene quantum dots, and mesoporous silica to harmonize chemotherapy and photodynamic mechanisms; their results confirmed robust ROS production and suggest strong synergy under 808 nm laser activation. Innovative material design continues with Huang et al. [42], who demonstrated that coupling titanium carbide (Ti₃C₂) with irradiated graphitic carbon nitride markedly enhances photocatalytic ROS generation, achieving significant cytotoxicity in CAL‑27 tumor cells [47]. Additionally, Khorshidi et al. [47] improved singlet oxygen yield via selenium-decorated graphene quantum dots complexed with methylene blue, showing deep-tissue photodynamic efficacy and low dark toxicity [48]. Emerging delivery strategies further strengthen this trend: Liu et al. [48] used red blood cell membrane-coating to enhance tumor targeting of g‑C₃N₄–red phosphorus composites, achieving 89% HeLa cell apoptosis under 660 nm irradiation with minimal systemic toxicity. Additionally, Qi et al. [49] demonstrated that ultrathin g‑C₃N₄ nanosheets enhanced blood–brain barrier permeability and ROS-induced tumor ablation in glioma models. Collectively, these studies affirm that graphene-based nanomaterials are rapidly advancing PDT from conceptual frameworks to highly targeted, clinically relevant platforms—a clear indicator that photodynamic therapy is an emerging and transformative theme in the field. Clinical evidence and translational constraints Despite the rapid expansion of graphene-based cancer research, clinical translation remains limited. The overwhelming majority of publications focus on preclinical studies involving in vitro models or small-animal systems, while clinical evidence is scarce. A search of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) reveals fewer than 10 registered trials directly involving graphene-based nanomaterials in oncology, and none have yet advanced to regulatory approval for systemic cancer therapy. Translational progress has been somewhat more visible in diagnostic and assistive domains, such as biosensors and imaging probes, where graphene oxide and graphene quantum dots have shown promise in biomarker detection and photothermal imaging. By contrast, systemic therapeutic applications face significant barriers, including unresolved safety and toxicology concerns (e.g., biodistribution, long-term clearance, immune activation), as well as challenges in large-scale manufacturing, reproducibility, and batch-to-batch consistency. These constraints define the present boundary of clinical applicability and highlight the translational gap between laboratory innovation and patient care. Addressing these issues will require interdisciplinary collaboration, standardized toxicological assessments, and alignment with regulatory frameworks to ensure graphene-based strategies move beyond proof-of-concept studies toward clinical implementation. Despite its comprehensive scope, this study is limited by its reliance on Scopus, potentially excluding relevant works from other databases. The search strategy, while systematic, may have omitted studies using alternative terminologies. Furthermore, the exclusion of grey literature, conference papers, and clinical trial data restricts practical insights. Future research should integrate multi-database searches, include clinical datasets, and apply machine learning techniques to map translational progress and assess real-world impact of graphene applications in oncology. It should be noted that while this study interprets declining recent-year citations primarily as a result of citation lag, future analyses could incorporate indicators such as citation velocity or field-normalised citation metrics. These measures would provide a more balanced view of scholarly influence, particularly in fast-moving interdisciplinary fields like graphene-based cancer research. Conclusion This bibliometric analysis provides a comprehensive overview of graphene-based cancer research between 2016 and 2025, confirming steady growth with China as the leading contributor in productivity and impact. The field’s interdisciplinary nature—anchored in chemistry, materials science, and biomedical sciences—demonstrates strong potential for translational advances in diagnostics and therapeutics. Core themes such as graphene oxide, drug delivery, and biosensing remain central, while the rise of plasmon resonance biosensors and label-free detection highlights a move toward real-time, precision-oriented oncology. Beyond consolidating knowledge structures, this study advances bibliometric approaches by combining co-citation, overlay, and trigram analyses to map thematic evolution and innovation. Importantly, the findings underscore the need to bridge laboratory progress with clinical translation through regulatory alignment, safety validation, and integration of socio-ethical and ecological considerations. Future research would benefit from multi-database bibliometric analyses to enhance coverage, systematic linkage with patent and clinical trial datasets to capture translational trajectories, and targeted funding for underrepresented regions to ensure equitable scientific advancement. By combining bibliometric insights with translational and policy perspectives, this work provides a strategic roadmap for researchers, clinicians, and policymakers to harness the full potential of graphene-based technologies in cancer care. Supplementary Information Supplementary material 1. Supplementary material 2. Supplementary material 3. Supplementary material 4. Supplementary material 5. Supplementary material 6. Supplementary material 1. Supplementary material 2. Supplementary material 3. Supplementary material 4. Supplementary material 5. Supplementary material 6.